SEC Form 4 · accession 0002127908-26-000004

Scribe Therapeutics, Inc. · SCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Mar 13, 2026

Accepted (ET)

Jul 27, 2026 · 9:20 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001853921

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 23, 2026	P	1,333	$15.00	A	1,333	I	By Spouse
Common Stock	Jul 23, 2026	P	1,333	$15.00	A	1,333	I	By Child

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1,F2	$19.13	Mar 13, 2026	A	8,909	A	—	Mar 12, 2036	Common Stock	8,909	8,909	D
Stock Option (Right to Buy)^F3	$15.00	Jul 23, 2026	A	109,426	A	—	Jul 22, 2036	Common Stock	109,426	109,426	D
Performance-based Stock Option (Right to Buy)^F4	$15.00	Jul 23, 2026	A	109,426	A	—	Jul 22, 2036	Common Stock	109,426	109,426	D

F1The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
F2The option is fully vested.
F3The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.